FD has received occasional consulting fees/honoraria and travel grants from BMS-Pfizer Alliance, Amgen, AstraZeneca, Bayer, Bouchara-Recordati, Bristol Myers Squibb, Boehringer Ingelheim, Menarini, Merck Sharp & Dohme, Novartis, Novo Nordisk, Organon, Pfizer, Sanofi, and Servier
Payers and pharmaceutical companies alike may need to explore new reimbursement strategies to meet patient needs and avoid exacerbating healthcare inequities
One study found that for every patient boarded, the median ED LOS for all admitted patients increased by at least 12 minutes
The alcohol industry is no longer about volume Either way, what this means for the alcohol industry is that the days of chasing volumes is over
This effect is not observed in other GLP-1RAs and is currently being studied by the drug manufacturers in the FOCUS trial (NCT03811561)